Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.
Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
- Conditions
- CNS Embryonal TumorCNS, MedulloblastomaAtypical Teratoid Rhabdoid TumorMedulloblastoma, ChildhoodMedulloblastoma, Group 3Medulloblastoma, Group 4PineoblastomaEmbryonal Tumor With Abundant Neuropil and True RosettesEpendymoblastomaMedulloepithelioma
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- C17 Council
- Target Recruit Count
- 15
- Registration Number
- NCT06942039
Efficacy and Safety of Celecoxib/Acetaminophen Versus Celecoxib for Diagnosed Osteoarthritis in Acute Exacerbation
- Conditions
- Joint PainKnee OsteoarthritisHip Osteoarthritis
- Interventions
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 231
- Registration Number
- NCT06863636
- Locations
- 🇲🇽
Laboratorio Silanes, S.A. de C.V., Mexico City, Mexico
Celecoxib for Prevention of Progression in Peutz-Jeghers Syndrome
- Conditions
- CelecoxibSmall Bowel PolypPeutz-Jeghers Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Air Force Military Medical University, China
- Target Recruit Count
- 80
- Registration Number
- NCT06722534
- Locations
- 🇨🇳
Xijing Hospital of Digestive Diseases, Air Force Military Medical University, Xi'an, Shaanxi, China
Stony Brook Medicine Anti-Inflammatory Trial
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Stony Brook University
- Target Recruit Count
- 42
- Registration Number
- NCT06699966
Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis
- Conditions
- Familial Adenomatous Polyposis
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 28
- Registration Number
- NCT06545526
- Locations
- 🇰🇷
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
Efficacy and Safety in the Combination of Celecoxib / Pregabalin / Vitamin B for Low Back Chronic Pain
- Conditions
- Chronic Low-back Pain
- Interventions
- Drug: Celecoxib+Pregabalin+Vitamin B fixed dose
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 192
- Registration Number
- NCT06516094
- Locations
- 🇲🇽
Laboratorio Silanes, S.A. de C.V., Mexico City, Mexico
Celecoxib for ENT Pain Management
- Conditions
- Parotidectomy
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 84
- Registration Number
- NCT06505187
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Shengyu Decoction and Lijin Manipulation for Knee OA: 3D Gait Analysis
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Other: Traditional Chinese medicine combined with manipulation treatment
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Xuhui Central Hospital, Shanghai
- Target Recruit Count
- 94
- Registration Number
- NCT06451783
- Locations
- 🇨🇳
Qiao Liang, Shanghai, China
Impact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries
- Conditions
- Postoperative Pain, AcutePain, Postoperative
- Interventions
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 70
- Registration Number
- NCT06379425
- Locations
- 🇺🇸
Northwell Health South Shore Surgery Center, Bay Shore, New York, United States
Impact of Opioid Avoidance Protocol for ACL Reconstruction
- Conditions
- ACL TearPost Operative Pain
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Matthew Varacallo
- Target Recruit Count
- 32
- Registration Number
- NCT06340932
- Locations
- 🇺🇸
Penn Highlands Dubois, DuBois, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.